To identify potential effective drug targets for breast cancer cell lines with low CDKN1B expression, the Genomics of Drug Sensitivity in Cancer (GDSC) database was used as an in vitro drug screening platform (Figure 1). This evidence concerns the gene CDKN1B and breast carcinoma.